REGN-COV2 is shorthand for REGN10933+REGN10987, a cocktail of two anti-spike monoclonal antibodies intended to block the ability of the SARS-CoV-2 virus to enter human cells. While a number of drugs before this have contained monoclonal antibodies, REGN10933 and REGN10987 are two of the first wave to be based on antibodies from convalescent and fully recovered people previously infected with SARS-CoV-2.
As we’ve noted in a previous story, “The Next Big Thing in COVID-19 Treatment: Here Come the Biologics!,” this class of new drugs has a name. REGN-COV2 is no longer the only “biologic” entering human trials, but this approach has been at the center of Tarrytown, New York based Regeneron Pharmaceutical’s efforts since the outset of the COVID-19 epidemic.
This week Regeneron was awarded a major grant to commence large scale production of REGN-COV2, pre-FDA approval, by BARDA, the Biomedical Advance Research and Development Authority. Regeneron’s REGN-COV2 production will likely take place at the company’s Rensselaer facility.
The related news, of interest to us, is that there are two clinical trial sites in The Bronx offering both inpatient and outpatient (at one of them) treatment. A third type for those living with someone with COVID who has not themselves tested positive is being set up. People who are interested in being drug trial participants should call 844-734-6643 and inquire of Regeneron directly.